None listed
Conditions
Interventions
Drug : Subjects who were randomly assigned to the trial group will receive 420 mg (regular dose, 140 mg x 3 pens) of evolocumab prior to primary percutaneous coronary intervention. It is continuously
Sponsors
BUCHEON SEJONG HOSPITAL
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) 30-80 years of age 2) >30 minutes in duration of typical chest pain 3) =1 mm of ST-segment elevation on = 2 contiguous leads 4) Onset of ischemic symptoms <12 hours ago 5) agree with study enrollment
Exclusion criteria
Exclusion criteria: 1) Prior myocardial infarction 2) Previous history of coronary artery bypass graft 3) Cardiogenic shock or cardiac arrest of more than 10 min 4) Acute left main coronary artery occlusion 5) Pregnancy or have a plan for pregnancy 6) Serum creatinine >2.5 mg/dL or hemodialysis is required 7) Expected survival < 1 year or poor compliance 8) Contraindication to cardiac MRI 9) previous administration of evolocumab within one month 10) body weight less than 40 kg 11) hypersensitivity or allergy to study drugs 12) active liver disease or high serum aminotransferase levels 13) genetic problems such as muscle disease, cyclosporin co-administration, galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| percent myocardial infarct size | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of microvascular obstruction;ST-segment resolution;Area under the curve of enzymatic infarct size;Myocardial blush grade;Corrected TIMI frame count;TIMI myocardial perfusion grade;CPK, Triglyceride, HDL-Cholesterol, LDL-Cholesterol, Hs-CRP, Lipoprotein(a) levels, P2Y12 reaction units levels | — |
Countries
Korea, Republic of
Contacts
Public ContactHyun Jong Lee
Sejong General Hospital
Outcome results
None listed